[PRESS RELEASE] – LONDON, Aug. 17, 2026 – Tilray Medical, a global leader in medical cannabis research, cultivation, production and distribution, and a division of Tilray Brands Inc., announced the U.K. launch of Tilray Medical-branded cannabis flower products through Lyphe Clinic and Lyphe Dispensary, creating a direct-to-patient channel that broadens access for patients across the country and supports the continued commercial growth of Tilray Medical-branded cannabis medicines in the U.K.
The launch marks an important milestone in Tilray’s integration of Lyphe Group and demonstrates the company’s differentiated medical cannabis platform in the U.K., bringing together European cultivation, pharmaceutical manufacturing, clinical care, prescribing, dispensing and patient support within a connected health care model.
Rajnish Ohri, president of international at Tilray Brands, said, “This launch is a defining step in Tilray Medical’s U.K. strategy and a powerful example of how we are building a more connected, patient-centered medical cannabis platform. By bringing Tilray Medical-branded cannabis medicines to patients through Lyphe Clinic and Lyphe Dispensary, we are combining high-quality European cultivation and pharmaceutical manufacturing with trusted clinical, prescribing, dispensing and patient care services. This integrated model strengthens responsible access for patients, supports health care practitioners and reinforces Tilray Medical’s commercial leadership in regulated medical cannabis markets.”
Tilray Brands acquired Lyphe Group in April 2026, establishing a differentiated U.K. medical cannabis platform spanning clinical care, prescribing, dispensing and pharmaceutical distribution. The addition of Tilray Medical products to Lyphe Clinic and Lyphe Dispensary strengthens this model by connecting Tilray Medical’s global production network with Lyphe’s established patient and pharmacy infrastructure.
The rollout reflects Tilray Medical’s commitment to responsible access across regulated international medical cannabis markets and leverages the scale, quality standards and supply-chain capabilities of its global operations. The range available through Lyphe Clinic and Lyphe Dispensary is expected to expand over the coming months, with Tilray Medical products cultivated and produced through the company’s international production network, including its EU-GMP-certified facility in Portugal.
